Fig. 3

Suppression of PDK1-NDRG1 signaling is associated with the response to combined trametinib and dexamethasone. a. MM.1S and MM.1R cells were treated with trametinib, dexamethasone or their combination for 48 h. Cell lysates were analysed in triplicate by RPPA for the indicated proteins. Hierarchical clustering of the log₂ fold-change in expression relative to the DMSO control is presented. b. Scatter plot of the log₂ fold-change in protein expression from the RPPA analysis comparing the MM.1S and MM.1R cells treated with the combination of trametinib and dexamethasone for 48 h. c. Decreased expression of candidate proteins for the combination of trametinib and dexamethasone relative to single agent treatment in MM.1S cells. Significance was determined by two-way Anova *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (n = 3). d. MM.1S and MM.1R cells were treated with DMSO, trametinib (30 nM), dexamethasone (100 nM) or their combination for 24, 48 and 72 h. Cell lysates were analysed by Western blotting for the indicated proteins. Data are representative of 3 independent experiments. Blot images were cropped for clarity of presentation